

References

<i>Ref. No.</i>	<i>Description</i>	<i>Volume</i>	<i>Page</i>
1.	Thompson WG, Longstreth GF, Drossman DA, et al. Functional bowel disorders and functional abdominal pain. <i>Gut</i> :1999;45(suppl II):143-147.	2	4
2.	The Burden of Gastrointestinal Diseases. AGA 2001 Chapter 4:27-29.	2	9
3.	Drossman DA, Whitehead WE, Camilleri M. Irritable bowel syndrome: A technical review for practice guideline development. <i>Gastroenterology</i> 1997;112:2120-2137.	2	13
4.	Camilleri M. Management of the irritable bowel syndrome. <i>Gastroenterology</i> 2001;120:652-668.	2	31
5.	Gralnek IM, Hays RD, Kilbourne A, et al. The impact of irritable bowel syndrome on health-related quality of life. <i>Gastroenterology</i> 2000;119:654-660	2	48
6.	Klein K. Controlled Treatment Trials in the Irritable Bowel Syndrome: A Critique. <i>Gastroenterology</i> 1988;95:232-241.	2	55
7.	Poynard T, Naveau S, Mory B, et al. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. <i>Alimen Pharmacol Ther</i> 1994;8:499-510	2	65
8.	Jailwala J, Imperiale TS, Kroenke K. Pharmacologic treatment of the irritable bowel syndrome: A systematic review of randomized clinical trials. <i>Ann Intern Med</i> 2000;133:136-147	2	76
9.	Jackson JL, O'Malley PG, Tomkins G, et al. Treatment of functional gastrointestinal disorders with antidepressant medications: a meta-analysis. <i>Am J Med</i> 2000;108:65-72.	2	88
10.	Akehurst R, Kaltenthaler E. treatment of irritable bowel syndrome: A review of randomized controlled trials. <i>GUT</i> 2001;48:272-282.	2	96
11.	Mangel AW., Northcutt, AR., Kong, S., et al. Validation of adequate relief as an endpoint in irritable bowel syndrome. <i>Gastroenterology</i> 1999;116:G4500	2	107
12.	Lembo T, Wright RA, Alosetron Investigator Team et al. Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant Irritable Bowel Syndrome. <i>Am J Gastroenterol</i> 2001;96:2662-2670.	2	108
13.	AGA technical review on intestinal ischemia. <i>Gastroenterology</i> 2000;118:954-968.	2	117

References

<i>Ref. No.</i>	<i>Description</i>	<i>Volume</i>	<i>Page</i>
14.	Grennwald DA, Brandt LJ. Colonic ischemia. Journal of Clinical Gastroenterology 1998;2:22-28.	2	132
15.	Laine L. Approaches to nonsteroidal anti-inflammatory drug use in the high risk patient. Gastroenterology 2001;120:594-606.	2	139
16.	Gottlieb S. COX 2 inhibitors may increase risk of heart attack. BMJ. 2001;323(7311):471.	2	152
17.	Mayer, EA. Some of the challenges in drug development for irritable bowel syndrome. GUT 2001;48:585-586.	2	153
18.	Camilleri M, Chey WY, Mayer E, et al. A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome. Arch Int Med 2001;161:1733-1740.	2	155